Key takeaways Animal studies show BPC-157 improves gastric motility and protects against gastric damage in rats No human clinical trial has tested BPC-157 for gastroparesis specifically BPC-157 modulates the nitric oxide system and may interact with vagal nerve function, both relevant to gastroparesis Oral administration (250-500 mcg daily) is preferred over injection for GI-targeted effects BPC-157 is unusually stable in stomach acid, making oral delivery viable Patients should work with their gastroenterologist before adding BPC-157 to their gastroparesis management What is gastroparesis and why is it hard to treat
They may also be used for diabetes, hypogonadism, and metabolic disorders
Withdrawal period Not applicable Storage Seal and protect from light
[6] [8] Thymosin beta-4 has also been reported to down-regulate inflammatory cytokines and reduce apoptosis and fibrosis effects framed differently from BPC-157s cytoprotective, nitric-oxide-centered profile
Step 2: Draw 2 mL of BAC water into a 3 mL syringe
Why the Combination Works BPC-157 excels at localized tissue repair, collagen enhancement, and concentrated effects near the injection site